ACK1 is a promising therapeutic target in cancer, including colorectal cancer (12), breast cancer, hepatocellular carcinoma (13), gastric cancer (14–16), ovarian cancer, and NSCLC (17, 18). This evidence concerns the gene TNK2 and non-small cell lung carcinoma.